CAPR News & Events

The major averages closed fractionally lower amid another wave of weakness hitting large-cap technology and semiconductor stocks. Of note, President Donald Trump in a social media post threatened a 100% tariff on European countries imposing a digital services tax on American companies.Outside of technology, falling oil prices are acting as a stabilizing force. Crude has moved toward multi-month lows as supply concerns continue easing, helping reduce some inflation pressure and potentially improving the broader economic outlook.Meanwhile, President Trump said on Truth Social that Iran shot "at least four" drones at ships crossing the Strait of Hormuz, with the president saying the U.S. "knocked down" three drones, while one of the drones "solidly" hit the upper deck of a large cargo ship. The drone attacks were "a foolish violation" of the countries' ceasefire agreement, he added.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:On SemiSynapticsin a $7B all-stock transactionFedEx FreightreportedOpenAI is leaning toward waiting until next year for its IPO,Troy Rohrbaugh has become the leading contender to succeed Jamie Dimon as CEO of JPMorgan,Qualcommexecutive vice president Durga Malladithat the company plans to use the new chip technology it created for data centers in smartphones2. WALL STREET CALLS:KeyBancNikeon longer than expected turnaroundCrocsto Overweight at Piper SandlerRobinhoodwith a Buy at BTIGAMHto Outperform at BMO CapitalVisteonto Neutral at Baird3. AROUND THE WEB:Boeinghas secured a $3.62B order from China Southern Airlines for freighter aircraft, including two 777F and five 777-8F models, along with options for three additional 777-8Fs, Bloomberg reportsUnileveris exploring a bid for Thorne, the supplements maker valued at up to $4B, and is among several bidders circling the brand, which has been put up for sale by its private equity owner L Catterton, FT reportsMetais working to replace human moderation with generative AI, FT saysGoogleis asking publishers that test new AI features in Google News to grant it broad rights to their content, including to potentially train AI models, The Information reportsVolkswagenCEO Oliver Blume is targeting a major restructuring that could include cutting up to 100,000 jobs, closing four German plants, and reducing planned five-year investment by about 15% to just over EUR130B, Reuters reports4. MOVERS:FuelCellincreased after Jefferiesthe stock to BuyAcadia Pharmaceuticalsgained after announcing Daybu wasin the EU by CHMPInfleqtionwas higher after Wedbushcoverage of the stock with an Outperform ratingBraksemwas lower in New York after filing for anCapricorfell afterfrom its HOPE-2 open-label extension study and announcing the FDA is planning to convene an advisory committee meeting to discuss the company's BLA for Deramiocel5. EARNINGS/GUIDANCE:Beyond Airand narrowed its guidance for FY26American Outdoor Brands, with CEO Brian Murphy commenting, "we are encouraged by the strength of our brands and the favorable consumer demand reflected in our POS results"Wisereportedand provided guidance for FY27Cineverse, with EPS and revenue higher year-over-yearApogee Enterprises, with CEO Donald Nolan commenting, "Our results for the quarter reflect solid execution as our team effectively navigated a dynamic operating environment"INDEXES:The Dow fell 44.51, or 0.086%, to 51,876.11, the Nasdaq lost 60.99, or 0.24%, to 25,297.62, and the S&P 500 declined 3.47, or 0.047%, to 7,354.02.

The major averages were fractionally higher near noon despite another wave of weakness hitting large-cap technology and semiconductor stocks. Outside of technology, falling oil prices are acting as a stabilizing force. Crude has moved toward multi-month lows as supply concerns continue easing, helping reduce some inflation pressure and potentially improving the broader economic outlook.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:On SemiSynapticsin a $7B all-stock transactionFedEx FreightreportedOpenAI is leaning toward waiting until next year for its IPO,Troy Rohrbaugh has become the leading contender to succeed Jamie Dimon as CEO of JPMorgan,Rocket Labwas selected by NASA tofor two separate NASA missions - PolSIR and TSIS-2 - from early next year2. WALL STREET CALLS:KeyBancNikeon longer than expected turnaroundCrocsto Overweight at Piper SandlerRobinhoodwith a Buy at BTIGAMHto Outperform at BMO CapitalVisteonto Neutral at Baird3. AROUND THE WEB:Boeinghas secured a $3.62B order from China Southern Airlines for freighter aircraft, including two 777F and five 777-8F models, along with options for three additional 777-8Fs, Bloomberg reportsUnileveris exploring a bid for Thorne, the supplements maker valued at up to $4B, and is among several bidders circling the brand, which has been put up for sale by its private equity owner L Catterton, FT reportsMetais working to replace human moderation with generative AI, FT saysGoogleis asking publishers that test new AI features in Google News to grant it broad rights to their content, including to potentially train AI models, The Information reportsVolkswagenCEO Oliver Blume is targeting a major restructuring that could include cutting up to 100,000 jobs, closing four German plants, and reducing planned five-year investment by about 15% to just over EUR 130B, Reuters reports4. MOVERS:FuelCellincreases after Jefferiesthe stock to BuyAcadia Pharmaceuticalsgains after announcing Daybu wasin the EU by CHMPInfleqtionhigher after Wedbushof the stock with an Outperform ratingBraksemlower in New York after filing for anfrom creditorsCapricor (CAPR) falls after presentingfrom its HOPE-2 open-label extension study and announcing the FDA is planning to convene an advisory committee meeting to discuss the company's BLA for Deramiocel5. EARNINGS/GUIDANCE:Beyond Airand narrowed its guidance for FY26American Outdoor Brands, with CEO Brian Murphy commenting, "we are encouraged by the strength of our brands and the favorable consumer demand reflected in our POS results"Wiseand provided guidance for FY27Cineverse, with EPS and revenue higher year-over-yearApogee Enterprises (APOG), with CEO Donald Nolan commenting, ""Our results for the quarter reflect solid execution as our team effectively navigated a dynamic operating environment"INDEXES:Near midday, the Dow was up 0.23%, or 118.98, to 52,039.60, the Nasdaq was up 0.22%, or 56.16, to 25,414.76, and the S&P 500 was up 0.24%, or 17.60, to 7,375.09.

Capricor Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration is planning to convene an advisory committee meeting to discuss the Company's Biologics License Application seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy. The BLA is supported by the Company's Phase 2 HOPE-2 trial and long-term outcomes from the HOPE-2-OLE trial, as well as positive results from the Phase 3 HOPE-3 trial, which achieved statistical significance on its primary endpoint, the key secondary cardiac endpoint, and all other Type I error-controlled secondary endpoints. The date for the Advisory Committee meeting is July 29, and the meeting will be available for live streaming.

Capricor Therapeutics announced five-year data from its ongoing HOPE-2 open-label extension study of Deramiocel, the company's lead cell therapy candidate for Duchenne Muscular Dystrophy, or DMD. The data will be presented at the Parent Project Muscular Dystrophy annual conference, taking place June 25-27 in Orlando, Florida, alongside previously reported results from the company's HOPE-3 Phase 3 trial. Among the patients who remain enrolled in the HOPE-2 OLE study, treatment with Deramiocel continued to attenuate disease progression over five years, as measured by Performance of the Upper Limb. Patients experienced a mean total-score decline of less than five points over five years. By comparison, a cohort-matched external comparator of standard-of-care DMD patients showed a modeled decline of roughly 2.4 points per year, which if continued would project to approximately 12 points over five years. A separately published natural-history analysis reported a decline in non-ambulant patients of approximately 8.1 points over three years, consistent with a meaningful treatment benefit. Cardiac function, as measured by left ventricular ejection fraction on cardiac MRI, remained stable over the full five-year period, in contrast to the modeled decline of approximately 3.2% per year observed in a propensity-matched external cardiac comparator. Deramiocel continued to demonstrate a favorable safety profile throughout the study, consistent with over 800 intravenous infusions administered to date across the Deramiocel clinical development program.